Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Interviews from EAU 2017

London, UK, 24 – 28 March 2017

  • Interview with Prof. Arnaulf Stenzl at EAU 2017 - New approach for treatment of non muscle invasive bladder cancer (NMIBC)

    Non-muscle invasive bladder cancer (NMIBC) is a common form of bladder and urothelial cancer is usually treated with less care than it should be. A new approach to this frequent condition is to have a perfect primary resection using techniques such as en bloc resection (EBR) and “sterilization” of floating cells during or after resection with adjuvant instillation therapy. In this video, Prof. Stenzl summarizes the benefits of transurethral EBR as a surgical intervention for NMIBC versus the standard surgical procedures in terms of better patient outcomes in the long term.
  • Interview with Prof. Arnaulf Stenzl at EAU 2017 - News in immunotherapy and combination therapy in urothelial cancer

    Urothelial cancer can be usually treated regionally using traditional approaches such as radiation, surgery and cisplatin based chemotherapy in majority of the cases. However, in case of aggressive tumours, discernment of their molecular patterns early in therapy might be a better approach to help decide the quantity and sequence of the various available approaches mentioned earlier. Recently, there has been an immense focus on checkpoint inhibitors such as PD-L1 which avoid the blockage of the immune system by the cancerous tumour. This treatment option either alone or in combination with other forms of therapy should be considered in the early stages of the disease especially in patients who cannot tolerate cisplatin based therapies. This interview with Prof. Stenzl focuses on the new wave of checkpoint inhibitors and what value they add to the oncology treatment arsenal.
  • Interview with Prof. Christopher Chapple - News from the EAU - The EAU's current activities in the field of oncology

    Oncology is a very important topic for urologists and this video features Prof. Christopher Chapple, the General Secretary for EAU discussing the work EAU is doing in field of urological oncology. He discusses, for example, the EAU activities for prostate cancer such as the development of a white paper, funding epidemiological studies and basic research. Additionally, he also mentions the future projects of the EAU such as the development of a reference network of urologists to study rare urological cancers such as penile cancer. He, thus, highlights the multidisciplinary role of the EAU in terms of working with various patient groups, clinicians, researchers and governments to provide better care in urological oncology.
  • Interview with Prof. Christopher Chapple - Breaking News and Highlights from EAU 2017

    In this video, Prof. Christopher Chapple summarizes the important sessions and their take-home messages from the EAU Congress 2017. He gives an overview of two plenary sessions which focussed on lower tract symptoms in men with benign prostatic disease and on management of underactive bladder respectively. He concludes that EAU 2017 has been a fantastic meeting which evaluated evidence base from the guidelines and which also looked at new emerging treatments to emphasize the best possible way to treat patients with urological disorders.
  • Interview with Prof. Maurizio Brausi - Surgery in uro-oncology - open surgery vs. robotic surgery

    Recently, there has been a lot of discussion with regards to better and effective surgical techniques in urological oncology such as open surgery versus robotic surgery. In this video, Prof. Maurizio Brausi discusses the debate session in EAU 2017 on the indications of open surgery and robotic surgery in various urological cancers such as prostate, bladder and kidney. He concludes that the evidence base for robotic surgery is still in a nascent stage and though it may become a standard care in prostate cancer, it is yet to fully establish itself in the management of kidney and bladder cancer.
  • Interview with Prof. Mark Babjuk - EAU guidelines for non muscle invasive bladder cancer (NMIBC)

    EAU recently released guidelines on non-muscle invasive bladder cancer (NMIBC) which were discussed at the EAU 2017 Congress. The guidelines committee was headed by Prof. Marek Babjuk and this video features him talking about the salient points of the EAU guidelines especially the position of transurethral surgery. He highlights the importance of the surgical techniques such as en bloc resection (EBR) to remove tumours in bladder cancer. He also stresses on the advantages of EBR in terms of not only achieving a high quality surgery but also obtaining a high quality sample for pathological investigation of the tumour.